Q32 Bio
Kelly Fahnoe has been working in the field of protein science since 2001. Kelly began their career at Pfizer Global Research & Development as a Scientist. In 2011, they joined Celgene as a Scientist II and Avila Tx (acquired by Celgene 2012) as a Principal Research Associate. In 2017, they joined Q32 Bio Inc. as Associate Director of Protein Science and a Senior Scientist, and also joined a Start up at Atlas Ventures as a Senior Scientist.
Kelly Fahnoe obtained a Bachelor of Science (B.Sc.) in Chemistry from Michigan State University between 1997 and 2001.
Q32 Bio
1 followers
Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases.